2026 Nobel Prize in Physiology or Medicine Announced, A-Share Companies Investing in Related Fields

Table of Contents

• You might want to know


• Main Topic


• Key Insights Table


• Afterwards...

You might want to know

1. How do the Nobel-winning discoveries in light-gated ion channels and optogenetics translate into clinical and commercial opportunities?

2. Which A-share companies are already pursuing technologies or products that leverage optogenetic principles for neurological and vision-related therapies?

Main Topic

On October 5 (local time), the Karolinska Institute in Sweden awarded the 2026 Nobel Prize in Physiology or Medicine to Karl Deisseroth, Peter Hegemann, and Georg Nagel for their work on light-gated ion channels and the development of optogenetics. The three laureates will share the prize money of 12 million Swedish kronor (approximately RMB 8.02 million). Their discoveries have provided new tools to probe and control neural circuits with light, transforming basic neuroscience and opening pathways toward clinical applications.

Optogenetics is a technique that uses genetically encoded, light-sensitive proteins to activate or inhibit neurons with high temporal and spatial precision. The milestone work began when Peter Hegemann and Georg Nagel identified an extraordinary protein—channelrhodopsin—within single-celled algae. Channelrhodopsins are light-gated ion channels that change neuronal membrane potential in response to specific wavelengths of light. Karl Deisseroth adapted these proteins into functional optical switches for neurons, enabling researchers to selectively control neuronal populations in living brains. This combination of discovery and engineering is what underpins modern optogenetics.

The scientific impact of optogenetics is vast. By enabling direct activation or silencing of defined cell types, researchers have been able to map neural circuits that govern memory, emotion, movement, and a variety of behaviors—many of which are implicated in neurological and psychiatric disorders. Optogenetic approaches have clarified causal relationships between specific neuronal pathways and behavioral outcomes, rather than relying solely on correlative data. This has deepened our mechanistic understanding of disease processes and pointed to targeted intervention strategies.

Clinically, optogenetic insights are beginning to inform therapeutic development. One promising translational avenue is restoring sight in patients with retinal degenerative diseases. Rather than replacing lost photoreceptors, optogenetic strategies aim to confer light sensitivity on surviving retinal cells by delivering genes that encode light-responsive proteins. Early clinical work and regulatory progress in this space indicate feasibility: researchers and companies have progressed to human trials to evaluate safety and evidence of functional vision recovery. Beyond vision, optogenetic principles are informing neuromodulation techniques for conditions such as Parkinson’s disease, epilepsy, chronic pain, and certain psychiatric conditions. While direct optogenetic therapies in the brain require safe, targeted gene delivery and effective light-delivery systems, hybrid approaches—such as closed-loop brain–machine interfaces that incorporate optogenetic control or chemogenetic variants—are under exploration.

In China’s A-share market, several listed companies have positioned themselves in related fields, either through direct development, investment in startups, or collaborative partnerships. These corporate engagements span gene therapy pipelines, device-assisted neuromodulation platforms, and integrated research initiatives that combine brain–computer interface (BCI) technologies with optogenetic concepts. For example:

• Haitai Biotech (海特生物) has an affiliate whose lead product, ZM-02, is a next-generation optogenetic gene therapy designed to treat advanced retinal degenerative diseases. ZM-02 received approval from the national drug regulator in August to begin clinical trials in China. Previously, the therapy received orphan drug designation from the U.S. FDA and obtained clearance to proceed to clinical studies abroad. This trajectory highlights cross-border regulatory engagement and suggests potential pathways for multinational development.



• Boto Biotech (博拓生物) has invested in or partnered with Genda Jiuzhou (健达九州), a company pursuing both chemogenetic and optogenetic neuromodulation approaches. Genda Jiuzhou’s optogenetic core program, GA001, recently completed the safety evaluation for the first participant dosed in a registration-type clinical trial. In addition, Boto Biotech and Genda Jiuzhou signed a strategic cooperation framework to advance clinical development and global positioning of GA003, a gene therapy candidate targeting substance use disorders. These collaborations demonstrate how private capital and public biotech firms can accelerate translational pipelines by sharing resources and expertise.



• China National Information (中科信息) has established a dedicated laboratory—the Chengdu Brain Cognition and Smart Healthcare Innovation Application Laboratory—that integrates brain–computer interface technologies and related equipment. The company is exploring closed-loop BMI systems that incorporate optogenetic modulation as an auxiliary tool, with target application scenarios including intelligent anesthesia management and smart rehabilitation. Such integrative research programs highlight how device, software, and biological modalities can converge to create next-generation therapeutic platforms.

These examples show different modes of engagement: direct development of optogenetic gene therapies for retinal disease, investment into startups pursuing both optogenetic and chemogenetic neuromodulation, and institutional R&D that links BMI devices with optogenetic control strategies. Each pathway faces common technical and regulatory challenges, including safe and efficient gene delivery vectors, sustained and controllable expression of light-sensitive proteins, device engineering for safe light delivery to target tissues, and the ethical and safety evaluations needed for human neural interventions.

At the same time, progress in related enabling technologies—improvements in viral vectors, advances in minimally invasive optics and implantable devices, and refinements in cell-type specific promoters—are steadily reducing barriers. Regulatory milestones, such as clinical trial approvals and orphan designations, provide important validation steps and can attract additional funding, strategic partnerships, and international collaboration. For companies listed on A-share exchanges, successful clinical readouts or regulatory approvals could meaningfully affect valuations and investor interest, especially as optogenetic approaches move from proof-of-concept to demonstrable patient benefit.

Looking at the broader landscape, the Nobel recognition emphasizes both fundamental discovery and translational potential. The scientific community has a clarified toolbox to dissect neural circuits, and industry players are exploring paths to convert mechanistic insights into therapies and medical devices. While timelines for clinical impact vary by indication and technical approach, the momentum is clear: the foundational science honored by the Nobel Prize is catalyzing a wave of preclinical and clinical activity that bridges neuroscience, gene therapy, and medical devices.

Key Insights Table

Afterwards...

The 2026 Nobel Prize highlights a pivotal set of discoveries that bridge basic neuroscience and potential clinical practice. For industry stakeholders, particularly A-share companies already active in gene therapy, neuromodulation, and brain–computer interface technologies, there is an opportunity to accelerate translational programs by addressing technical hurdles and pursuing rigorous clinical development. Collaborations between biotech firms, device manufacturers, research institutions, and regulatory bodies will be key to moving promising optogenetic and related therapies from experimental settings to safe, effective treatments for patients. Continued investment in vector technology, light-delivery systems, and ethical frameworks will determine how rapidly and responsibly these innovations reach clinical impact.